T1	p 100 135	patients with early breast cancer :
T2	p 213 218	Group
T3	p 221 226	CECOG
T4	p 323 347	with early breast cancer
T5	i 25 96	dose-dense FEC regimens with growth factor support for adjuvant therapy
T6	i 243 278	epirubicin to adjuvant chemotherapy
T7	i 517 520	FEC
T8	i 551 554	FEC
T9	i 601 613	chemotherapy
T10	i 618 621	FEC
T11	i 696 734	intermediate dose-dense FEC regimens .
T12	i 777 801	FEC ( 75 ) or FEC ( 90 )
T13	i 809 830	all three drugs given
T14	i 886 904	pegfilgrastim 6 mg
T15	i 1124 1127	FEC
T16	i 1139 1142	FEC
T17	i 1179 1182	FEC
T18	i 1242 1245	FEC
T19	i 1413 1416	FEC
T20	i 1524 1527	FEC
T21	i 1759 1762	FEC
T22	i 1856 1870	dose-dense FEC
T23	i 1882 1885	FEC
T24	o 977 985	efficacy
T25	o 1317 1363	adverse events and personal/logistical reasons
T26	o 1439 1486	diarrhoea . Grade 3-4 haematological toxicities
T27	o 1566 1588	of febrile neutropenia
T28	o 1632 1638	events
T29	o 1657 1700	liver enzymes and gastrointestinal events ;
T30	o 1784 1839	serious adverse events ( vomiting and throat oedema ) .
T31	o 1989 2009	Grade 3-4 toxicity .